Hertz, D L
Kidwell, K M
Seewald, N J
Gersch, C L
Desta, Z
Flockhart, D A
Storniolo, A-M
Stearns, V
Skaar, T C
Hayes, D F
Henry, N L
Rae, J M
Article History
Received: 18 November 2015
Revised: 13 June 2016
Accepted: 15 June 2016
First Online: 23 August 2016
Competing interests
: Dr Stearns has received research funding from Abbvie, Celgene, Merck, Novartis, Medimmune, Pfizer and Puma. NLH had research funding from AstraZeneca, Eli Lilly, BioMarin Pharmaceuticals, Celldex Pharmaceuticals, and Sanofi Aventis. VS had research funding from Abbvie, Abraxis (Celgene), Medimmune, Merck, Novartis, Pfizer, Puma. DFH has consulted for Pfizer and Lilly Oncology, and had research funding from Janssen R&D, Puma Biotechnology, Pfizer, and Astra Zeneca. DFH also has personal financial interest in Oncimmune and Inbiomotion and has royalties from Janssen R&D. DAF had research funding from Pfizer and Novartis and sat on the Scientific Board for Quest Diagnostics. The other authors declare no conflict of interest.